Sivik Global Healthcare LLC Takes Position in CG Oncology, Inc. $CGON

Key Points

• Sivik Global Healthcare established a new stake in CG Oncology in Q4, buying 35,000 shares worth about $1.45 million; institutional investors now own roughly 26.56% of the company.
• Analysts have a consensus rating of "Moderate Buy" with an average price target of $70.67, while individual targets range up to $93 (Morgan Stanley) and several firms maintain buy/outperform views.
• CG Oncology is trading near its one‑year high (~$69.8) with a $5.89 billion market cap and a negative P/E; the company beat quarterly EPS estimates (‑$0.51 vs. ‑$0.61) on $2.32 million in revenue, and insiders own about 7.4% after a recent director sale.

Sivik Global Healthcare LLC bought a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 35,000 shares of the company's stock, valued at approximately $1,453,000.

A number of other hedge funds have also recently modified their holdings of the business. Strengthening Families & Communities LLC purchased a new position in CG Oncology during the 3rd quarter valued at about $40,000. Tower Research Capital LLC TRC lifted its position in CG Oncology by 159.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company's stock valued at $182,000 after acquiring an additional 4,288 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new position in CG Oncology during the 3rd quarter valued at about $208,000. Sei Investments Co. purchased a new position in shares of CG Oncology during the second quarter valued at approximately $209,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of CG Oncology during the third quarter valued at approximately $211,000. Institutional investors own 26.56% of the company's stock.

Wall Street Analyst Weigh In

CGON has been the subject of several recent research reports. Royal Bank Of Canada lifted their target price on shares of CG Oncology from $61.00 to $73.00 and gave the company an "outperform" rating in a report on Wednesday, January 21st. Wall Street Zen lowered shares of CG Oncology from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CG Oncology in a report on Wednesday, January 21st. The Goldman Sachs Group reiterated a "buy" rating and set a $82.00 target price on shares of CG Oncology in a report on Monday, January 12th. Finally, Morgan Stanley set a $93.00 price objective on shares of CG Oncology in a research note on Friday, January 9th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CG Oncology has a consensus rating of "Moderate Buy" and an average price target of $70.67.

CG Oncology Price Performance

CG Oncology stock opened at $69.81 on Wednesday. CG Oncology, Inc. has a one year low of $14.80 and a one year high of $69.90. The stock has a market capitalization of $5.89 billion, a PE ratio of -33.72 and a beta of 0.70. The business's fifty day moving average is $59.73 and its 200 day moving average is $48.88.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter. As a group, sell-side analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Insider Activity at CG Oncology

In related news, Director James Mulay sold 1,964 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $63.50, for a total transaction of $124,714.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 7.40% of the stock is owned by company insiders.

CG Oncology Company Profile

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

Want to see what other hedge funds are holding CGON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CG Oncology, Inc. (NASDAQ:CGON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.